Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia

NCT03330691 is registered in ClinicalTrials.gov with Seattle Children's Hospital as lead sponsor.

NCT NCT03330691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03330691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia
Lead sponsor
Seattle Children's Hospital
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 3, 2017
Completion date
March 3, 2035
Enrollment
78 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoma